BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being ...
JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp in ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Larimar Therapeutics, Inc. has announced a refined timeline for submitting a Biologics License Application (BLA) for its treatment nomlabofusp, aimed at addressing Friedreich's Ataxia (FA). Based on ...
Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Larimar Therapeutics (LRMR) to $18 from $22 and keeps an Outperform rating on the shares. Larimar will have new open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback